Cargando…
Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes
Although mutant-specific T cells are elicited in some individuals infected with HIV-1 mutant viruses, the detailed characteristics of these T cells remain unknown. A recent study showed that the accumulation of strains expressing Nef135F, which were selected by HLA-A*24:02-restricted T cells, was as...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577379/ https://www.ncbi.nlm.nih.gov/pubmed/34523962 http://dx.doi.org/10.1128/JVI.01259-21 |
_version_ | 1784596051896827904 |
---|---|
author | Kuse, Nozomi Murakoshi, Hayato Akahoshi, Tomohiro Chikata, Takayuki James, Katherine L. Gatanaga, Hiroyuki Rowland-Jones, Sarah L. Oka, Shinichi Takiguchi, Masafumi |
author_facet | Kuse, Nozomi Murakoshi, Hayato Akahoshi, Tomohiro Chikata, Takayuki James, Katherine L. Gatanaga, Hiroyuki Rowland-Jones, Sarah L. Oka, Shinichi Takiguchi, Masafumi |
author_sort | Kuse, Nozomi |
collection | PubMed |
description | Although mutant-specific T cells are elicited in some individuals infected with HIV-1 mutant viruses, the detailed characteristics of these T cells remain unknown. A recent study showed that the accumulation of strains expressing Nef135F, which were selected by HLA-A*24:02-restricted T cells, was associated with poor outcomes in individuals with the detrimental HLA-B*35:01 allele and that HLA-B*35:01-restricted NefYF9 (Nef135-143)-specific T cells failed to recognize target cells infected with Nef135F mutant viruses. Here, we investigated HLA-B*35:01-restricted T cells specific for the NefFF9 epitope incorporating the Nef135F mutation. Longitudinal T-cell receptor (TCR) clonotype analysis demonstrated that 3 types of HLA-B*35:01-restricted T cells (wild-type [WT] specific, mutant specific, and cross-reactive) with different T cell repertoires were elicited during the clinical course. HLA-B*35:01(+) individuals possessing wild-type-specific T cells had a significantly lower plasma viral load (pVL) than those with mutant-specific and/or cross-reactive T cells, even though the latter T cells effectively recognized the mutant virus-infected cells. These results suggest that mutant-specific and cross-reactive T cells could only partially suppress HIV-1 replication in vivo. An ex vivo analysis of the T cells showed higher expression of PD-1 on cross-reactive T cells and lower expression of CD160/2B4 on the mutant-specific T cells than other T cells, implying that these inhibitory and stimulatory molecules are key to the reduced function of these T cells. In the present study, we demonstrate that mutant-specific and cross-reactive T cells do not contribute to the suppression of HIV-1 replication in HIV-1-infected individuals, even though they have the capacity to recognize mutant virus-infected cells. Thus, the collaboration of HLA-A*24:02 with the detrimental allele HLA-B*35:01 resulted in the coevolution of HIV-1 alongside virus-specific T cells, leading to poorer clinical outcomes. IMPORTANCE HIV-1 escape mutations are selected under pressure from HIV-1-specific CD8(+) T cells. Accumulation of these mutations in circulating viruses impairs the control of HIV-1 by HIV-1-specific T cells. Although it is known that HIV-1-specific T cells recognizing mutant virus were elicited in some individuals infected with a mutant virus, the role of these T cells remains unclear. Accumulation of phenylalanine at HIV-1 Nef135 (Nef135F), which is selected by HLA-A*24:02-restricted T cells, led to poor clinical outcome in individuals carrying the detrimental HLA-B*35:01 allele. In the present study, we found that HLA-B*35:01-restricted mutant-specific and cross-reactive T cells were elicited in HLA-B*35:01(+) individuals infected with the Nef135F mutant virus. These T cells could not effectively suppress HIV-1 replication in vivo even though they could recognize mutant virus-infected cells in vitro. Mutant-specific and cross-reactive T cells expressed lower levels of stimulatory molecules and higher levels of inhibitory molecules, respectively, suggesting a potential mechanism whereby these T cells fail to suppress HIV-1 replication in HIV-1-infected individuals. |
format | Online Article Text |
id | pubmed-8577379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85773792021-11-29 Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes Kuse, Nozomi Murakoshi, Hayato Akahoshi, Tomohiro Chikata, Takayuki James, Katherine L. Gatanaga, Hiroyuki Rowland-Jones, Sarah L. Oka, Shinichi Takiguchi, Masafumi J Virol Pathogenesis and Immunity Although mutant-specific T cells are elicited in some individuals infected with HIV-1 mutant viruses, the detailed characteristics of these T cells remain unknown. A recent study showed that the accumulation of strains expressing Nef135F, which were selected by HLA-A*24:02-restricted T cells, was associated with poor outcomes in individuals with the detrimental HLA-B*35:01 allele and that HLA-B*35:01-restricted NefYF9 (Nef135-143)-specific T cells failed to recognize target cells infected with Nef135F mutant viruses. Here, we investigated HLA-B*35:01-restricted T cells specific for the NefFF9 epitope incorporating the Nef135F mutation. Longitudinal T-cell receptor (TCR) clonotype analysis demonstrated that 3 types of HLA-B*35:01-restricted T cells (wild-type [WT] specific, mutant specific, and cross-reactive) with different T cell repertoires were elicited during the clinical course. HLA-B*35:01(+) individuals possessing wild-type-specific T cells had a significantly lower plasma viral load (pVL) than those with mutant-specific and/or cross-reactive T cells, even though the latter T cells effectively recognized the mutant virus-infected cells. These results suggest that mutant-specific and cross-reactive T cells could only partially suppress HIV-1 replication in vivo. An ex vivo analysis of the T cells showed higher expression of PD-1 on cross-reactive T cells and lower expression of CD160/2B4 on the mutant-specific T cells than other T cells, implying that these inhibitory and stimulatory molecules are key to the reduced function of these T cells. In the present study, we demonstrate that mutant-specific and cross-reactive T cells do not contribute to the suppression of HIV-1 replication in HIV-1-infected individuals, even though they have the capacity to recognize mutant virus-infected cells. Thus, the collaboration of HLA-A*24:02 with the detrimental allele HLA-B*35:01 resulted in the coevolution of HIV-1 alongside virus-specific T cells, leading to poorer clinical outcomes. IMPORTANCE HIV-1 escape mutations are selected under pressure from HIV-1-specific CD8(+) T cells. Accumulation of these mutations in circulating viruses impairs the control of HIV-1 by HIV-1-specific T cells. Although it is known that HIV-1-specific T cells recognizing mutant virus were elicited in some individuals infected with a mutant virus, the role of these T cells remains unclear. Accumulation of phenylalanine at HIV-1 Nef135 (Nef135F), which is selected by HLA-A*24:02-restricted T cells, led to poor clinical outcome in individuals carrying the detrimental HLA-B*35:01 allele. In the present study, we found that HLA-B*35:01-restricted mutant-specific and cross-reactive T cells were elicited in HLA-B*35:01(+) individuals infected with the Nef135F mutant virus. These T cells could not effectively suppress HIV-1 replication in vivo even though they could recognize mutant virus-infected cells in vitro. Mutant-specific and cross-reactive T cells expressed lower levels of stimulatory molecules and higher levels of inhibitory molecules, respectively, suggesting a potential mechanism whereby these T cells fail to suppress HIV-1 replication in HIV-1-infected individuals. American Society for Microbiology 2021-11-09 /pmc/articles/PMC8577379/ /pubmed/34523962 http://dx.doi.org/10.1128/JVI.01259-21 Text en Copyright © 2021 Kuse et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Pathogenesis and Immunity Kuse, Nozomi Murakoshi, Hayato Akahoshi, Tomohiro Chikata, Takayuki James, Katherine L. Gatanaga, Hiroyuki Rowland-Jones, Sarah L. Oka, Shinichi Takiguchi, Masafumi Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title | Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title_full | Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title_fullStr | Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title_full_unstemmed | Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title_short | Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes |
title_sort | collaboration of a detrimental hla-b*35:01 allele with hla-a*24:02 in coevolution of hiv-1 with t cells leading to poorer clinical outcomes |
topic | Pathogenesis and Immunity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577379/ https://www.ncbi.nlm.nih.gov/pubmed/34523962 http://dx.doi.org/10.1128/JVI.01259-21 |
work_keys_str_mv | AT kusenozomi collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT murakoshihayato collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT akahoshitomohiro collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT chikatatakayuki collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT jameskatherinel collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT gatanagahiroyuki collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT rowlandjonessarahl collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT okashinichi collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes AT takiguchimasafumi collaborationofadetrimentalhlab3501allelewithhlaa2402incoevolutionofhiv1withtcellsleadingtopoorerclinicaloutcomes |